Skip to content

Discontinued — last reported Q3 '21

Geographic · Operating Income

Corporate Functions — Operating Income

Zimmer Biomet Holdings Corporate Functions — Operating Income increased by 6.7% to -$151.2M in Q3 2021 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2019
Last reportedQ3 2021Nov 4, 2021
Rolls up toOperating Income

How to read this metric

An increase in operating loss indicates rising corporate overhead or administrative expenses, while a decrease suggests improved cost management or reduced central support requirements.

Detailed definition

This metric represents the operating income or loss generated by the corporate administrative and support functions that...

Peer comparison

Most large-cap medical device companies report similar unallocated corporate expenses, often labeled as 'Corporate' or 'Other' in segment reporting, which are typically evaluated as a percentage of total revenue to assess administrative leverage.

Metric ID: zbh_segment_corporate_functions_operating_income_loss

Historical Data

2 periods
 Q2 '21Q3 '21
Value-$162M-$151.2M
QoQ Change+6.7%
Range-$162M-$151.2M

Frequently Asked Questions

What is Zimmer Biomet Holdings's corporate functions — operating income?
Zimmer Biomet Holdings (ZBH) reported corporate functions — operating income of -$151.2M in Q3 2021.
What does corporate functions — operating income mean?
This is the net operating profit or loss resulting from the company's central administrative and corporate support activities.